Difference between BABE study and clinical trials [Design Issues]

posted by dshah  – India/United Kingdom, 2020-07-31 12:46 (1450 d 23:17 ago) – Posting: # 21813
Views: 4,845

Dear VijithRoy!
As rightly mentioned by Helmut, BABE studies are considered as Phase-I study. Generally the concept for generics to perform BABE study is to use the already available knowledge of Innovator for safety and efficacy.
Apart from BCS based biowaiver;
A- Parenteral (IV, IM, SC, IT) adm. as aqueous solution;
B- Solution for oral use,
C-Gas ,
D- Powder for reconstitution as a solution (Meeting above A or B)
E- Otic or ophthalmic or topical product prepared as an aqueous solution
and few other dosage forms can be considered for biowaiver where BE is self evident.
On the other hand, Q1/Q2/Q3 criteria may needs to be matched to Innovator (case to case basis).

Regards,
DShah

Complete thread:

UA Flag
Activity
 Admin contact
23,112 posts in 4,858 threads, 1,644 registered users;
61 visitors (0 registered, 61 guests [including 10 identified bots]).
Forum time: 12:04 CEST (Europe/Vienna)

It’s always fun to have your models validated,
but is way more fun to have them trashed.
Finding out you are completely wrong
is a great part of science.    G. Randall Gladstone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5